FindTrial
Sign In

An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in the extension study (A2301E1) in Japan and are judged by the investigator to benefit from continued QTI571 treatment

An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in the extension study (A2301E1) in Japan and are judged by the investigator to benefit from continued QTI571 treatment

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222412
Enrollment
Unknown
Registered
2014-03-03
Start date
2014-03-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

investigational material(s) Generic name etc : QTI571 INN of investigational material : imatinib Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigation

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient is receiving QTI571 for the treatment of PAH and is currently enrolled in the extension study (A2301E1) in Japan. 2. Patient is currently benefitting from the treatment with QTI571 in the opinion of the investigator.

Exclusion criteria

Exclusion criteria: 1. Patient has been permanently discontinued from QTI571 study treatment in the parent study. 2. Concomitant use of oral vitamin K antagonist medication.

Design outcomes

Primary

MeasureTime frame
Serious Adverse Events All Serious Adverse events will be evaluated and reported for all participants receiving QTI571—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026